top of page

Josbert KELLER





Gastroenterologist at Haaglanden Medical Center, The Hague

Founder and Board member of The Netherlands Donor Feces Bank (

Research appointment at Leiden University medical Center


1999                                 Medical Degree University of Amsterdam. Judicium: cum laude

2002                                 PhD thesis, Department of Pathology, University of Amsterdam

2002-2009                       Residency Internal Medicine & Gastroenterology, Academic Medical Center, Amsterdam


1994-1996                       Helicobacter pylori infection, Academic medical Center (AMC), Amsterdam

1996-2009                       Gastrointestinal polyposis syndromes, Department of Pathology (AMC) in collaboration with the Department of                     

                                          Gastroenterology, Johns Hopkins University, Baltimore

2006-2013                       Treatment of Clostridium difficile infection with Fecal Microbiota Transplantation     

                                          Principal investigator of Fecal Trial, N Engl J Med 2013; 368:407-415

2014-                                FMT and stool banking. Founder of Netherlands Donor Feces Bank (NDFB). The NDFB has initiated several studies addressing

                                          the effects of FMT for various disorders


2007-2009                        Netherlands Young GI section (NVMDL io), board member

2011-2017                        Secretary of the Netherlands Society of Gastroenterology (NVGE)

2013-2019                        Working Group “Quality Measures Colonoscopy” of the Netherlands colorectal cancer screening program

2013                                  Institute of Medicine’s Forum on Microbial Threats, Washington DC, 2013. “Microbial Ecology in States of Health and Chronic


2017 -                                Initiation and organization of Common Interest Group meetings about FMT during UEG week (2017, 2018, 2019)              

2017-2020                        Representative of National Societies Forum in de Meeting of Members of UEG

2018-2020                        Project leader of the UEG/EHMSG standards and guidelines Activity Grant: “Stool banking to facilitate safe and cost effective

                                           Fecal Microbiota Transplantation in Europe”

2019 -                                Member of the Gastrostart committee of NVGE, evaluating grant applications for innovative research



  • > 60 peer reviewed publications, selected publications:

  •  Van der Hulst, R. W., Keller, J. J., Rauws, E. A., Tytgat, G. N. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter., 1: 6-19, 1996.

  • Van der Hulst, R. W., Rauws, E. A., Koycu, B., Keller, J. J., Bruno, M. J., Tijssen, J. G., Tytgat, G. N. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology, 113: 1082-1086, 1997

  • Keller, J. J., Offerhaus, G. J., Drillenburg, P., Caspers, E., Musler, A., Ristimaki, A., Giardiello, F. M. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin. Cancer Res., 7: 4000-4007, 2001

  • Keller, J. J., Westerman, A. M., de Rooij, F. W., Wilson, J. H., van, D. H., Giardiello, F. M., Weterman, M. A., Offerhaus, G. J. Molecular genetic evidence of an association between nasal polyposis and the Peutz-Jeghers syndrome. Ann. Intern. Med., 136: 855-856, 2002

  • de Leng, W. W., Westerman, A. M., Weterman, M. A., de Rooij, F. W., Dekken, H. H., De Goeij, A. F., Gruber, S. B., Wilson, J. H., Offerhaus, G. J., Giardiello, F. M., Keller, J. J. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin. Cancer Res., 9: 3065-3072, 2003.

  • van Nood E, Vrieze A, Nieuwdorp Max, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ. Donor feces infusion in the duodenum for recurrent Clostridium difficile infections. New England Journal of Medicine 2013; 368:407-415

  • Keller JJ, Kuijper EJ. Treatment of recurrent and severe Clostridium difficile infection. Annu Rev Med. 2015;66:373-86.

  • Terveer EM, van Beurden YH, Goorhuis A, Seegers JFML, Bauer MP, van Nood E, Dijkgraaf MGW, Mulder CJJ, Vandenbroucke-Grauls CMJE, Verspaget HW, Keller JJ*, Kuijper EJ*. Development and first experiences of the Netherlands Donor Feces Bank. Clin Microbiol Infect 2017 Dec;23(12):924-930

  • Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical Application and Potential of Fecal Microbiota Transplantation. Annu Rev Med. 2019;70: 335-351

  • Keller JJ, Vehreschild MJ, Hvas CL, Jørgensen SM, Kupciskas J, Link A, Mulder CJ, Goldenberg SD, Arasaradnam R, Sokol H, Gasbarrini A, Hoegenauer C, Terveer EM, Kuijper EJ, Arkkila P; UEG working group of the Standards and Guidelines initiative Stool banking for FMT. Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. United European Gastroenterol J. 2019; 7(10):1408-1410

bottom of page